Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Cadazolid in Severe CDI
NCT02053181Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2012
- Primary completion
- Sep 2012
- Modality
- Bivalent/Multivalent Binders, Orthosteric Ligands, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cadazolid in Clostridioides difficile infection (CDI), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Maximum plasma concentration at 144 hours, Time to reach maximum plasma concentration at 144 hours and 3 more. Started Aug 2012; status: completed.
02
Drugs
cadazolid
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02053181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02053181.